Phase 2
Completed N=17
LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma
Source: ClinicalTrials.gov NCT00610883 ↗Enrolled (actual)
17
Serious AEs
5.9%
Results posted
Jan 2016
Primary outcomePrimary: Complete Remission — 10 participants
Summary
Non-Hodgin's lymphoma is curable in 76% of patients. In nonlymphoblastic lymphmas, cancer may return on average 3 months from beginning treatment and for lymphoblastic lymphomas, 6 months. To aggressively treat this cancer this study uses effective drugs in three parts:
* Induction ends on day 19
* Consolidation ends on day 38 or 42
* Maintenance may include up to 6 cycles
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Complete Remission |
10 | — |
Eligibility Criteria
Inclusion Criteria
- Non-Hodgkin's Lymphoma stages III, IV, IVA with
- T cell lymphomas, any primary site irrespective of LDH level
- large cell lymphomas, any primary site irrespective of LDH level
- B cell lymphomas, any primary site with initial LDH of less than 500
Exclusion Criteria
- B cell lymphomas, any primary site with initial LDH of less than 500 and initial CNS or bone involvement
Data sourced from ClinicalTrials.gov (NCT00610883). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.